Thymosin Alpha-1 vs Vasoactive Intestinal Peptide (VIP)
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Thymosin Alpha-1
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally derived from the thymus gland. It plays a central role in regulating immune function — specifically in the maturation and differentiation of T-cells. Unlike most research peptides, Thymosin Alpha-1 has approved clinical use in multiple countries (China, Italy, and others) for hepatitis B, hepatitis C, and as an immune adjuvant in cancer patients undergoing chemotherapy. In the US it is sold as Zadaxin and used as a research compound.
Full profileVasoactive Intestinal Peptide (VIP)
28-amino acid neuropeptide found throughout the CNS, gut, and immune system. Functions as a potent anti-inflammatory, vasodilator, and neurotrophic factor. Research applications include CIRS (Chronic Inflammatory Response Syndrome), pulmonary arterial hypertension, autoimmune conditions, and gut motility disorders. Intranasal administration is most studied for CIRS and neuroinflammatory conditions.
Full profile| Thymosin Alpha-1 | Vasoactive Intestinal Peptide (VIP) | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Tα1, Thymalfasin, Zadaxin | VIP, vasoactive intestinal polypeptide, PHM-27 |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | 900mcg–3.2mg mg, 2–3 times per week subcutaneously | 25mcg–100mcg mcg, Daily intranasal or 1–2x weekly subcutaneous |
| Administration | Subcutaneous injection | Intranasal spray, Subcutaneous injection, Inhalation (nebulized) |
| Key side effects | Generally very well tolerated, Mild injection site reactions (most common), Transient fatigue in initial doses, Flu-like symptoms (rare) | Facial flushing, Transient hypotension, Nasal irritation (intranasal route), Tachycardia |
| Cited sources | 4 references | 2 references |
Key differences
- Evidence level differs: Thymosin Alpha-1 is research-stage, while Vasoactive Intestinal Peptide (VIP) is investigational (in trials).
- Administration: Thymosin Alpha-1 — Subcutaneous injection; Vasoactive Intestinal Peptide (VIP) — Intranasal spray, Subcutaneous injection, Inhalation (nebulized).
- Dosing units differ: Thymosin Alpha-1 is dosed in mg, Vasoactive Intestinal Peptide (VIP) in mcg — they operate at different scales.
- Frequency: Thymosin Alpha-1 is typically 2–3 times per week subcutaneously; Vasoactive Intestinal Peptide (VIP) is Daily intranasal or 1–2x weekly subcutaneous.
- Research depth: this profile cites 4 sources for Thymosin Alpha-1 vs 2 for Vasoactive Intestinal Peptide (VIP).
How each works
Thymosin Alpha-1
Extensive human clinical research documents Tα1's immune-modulating effects. It increases T-cell counts, enhances NK cell activity, and promotes Th1 cytokine balance. Multiple randomized trials have shown efficacy in treating chronic hepatitis B and C, reducing infection severity in critically ill patients, and improving outcomes in sepsis. More recent research investigates its role in long COVID immune dysregulation. It is considered one of the best-studied peptides in immunology.
Vasoactive Intestinal Peptide (VIP)
VIP activates VPAC1 and VPAC2 receptors coupled to cAMP, suppressing pro-inflammatory cytokines while promoting Th2 regulatory immune responses and Treg differentiation. In the CIRS/biotoxin illness framework pioneered by Shoemaker, VIP intranasal formulation demonstrates normalization of inflammatory markers and improvement in TGF-β, MSH, and VIP deficiency seen in CIRS patients. Pulmonary vasodilation effects have been studied for PAH.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.